Agios Pharmaceuticals, Inc. unveiled another set of Phase III data showing efficacy for its pyruvate kinase inhibitor Pyrukynd (mitapivat) in thalassemia patients on 3 June, showing therapeutic benefit for patients with transfusion-dependent alpha or beta thalassemia, which it will file by the end of 2024 to expand its earlier approval in non-transfusion-dependent patients to cover all thalassemia patients.
Agios Shows Pyrukynd Can Reduce Transfusions In Thalassemia
Having already posted Phase III success in non-transfusion dependent patients, Agios’s Pyrukynd now has shown the ability to reduce transfusions in alpha and beta thalassemia patients.
